Reichardt JK - Search Results

1

Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study.

Pearce CL, Makridakis NM, Ross RK, Pike MC, Kolonel LN, Henderson BE, Reichardt JK. Pearce CL, et al. Among authors: reichardt jk. Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):417-8. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 11927504 No abstract available.

2

Molecular epidemiology of androgen-metabolic loci in prostate cancer: predisposition and progression.

Makridakis NM, Reichardt JK. Makridakis NM, et al. Among authors: reichardt jk. J Urol. 2004 Feb;171(2 Pt 2):S25-8; discussion S28-9. doi: 10.1097/01.ju.0000107844.78769.35. J Urol. 2004. PMID: 14713749 Review.

3

Identification and characterization of somatic steroid 5alpha-reductase (SRD5A2) mutations in human prostate cancer tissue.

Makridakis N, Akalu A, Reichardt JK. Makridakis N, et al. Among authors: reichardt jk. Oncogene. 2004 Sep 23;23(44):7399-405. doi: 10.1038/sj.onc.1207922. Oncogene. 2004. PMID: 15326487

4

Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.

Makridakis N, Reichardt JK. Makridakis N, et al. Among authors: reichardt jk. J Mol Endocrinol. 2005 Jun;34(3):617-23. doi: 10.1677/jme.1.01725. J Mol Endocrinol. 2005. PMID: 15956333

5

No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.

Pearce CL, Van Den Berg DJ, Makridakis N, Reichardt JK, Ross RK, Pike MC, Kolonel LN, Henderson BE. Pearce CL, et al. Among authors: reichardt jk. Hum Mol Genet. 2008 Aug 15;17(16):2456-61. doi: 10.1093/hmg/ddn145. Epub 2008 May 10. Hum Mol Genet. 2008. PMID: 18469342 Free PMC article.

6

Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk.

Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK. Reichardt JK, et al. Cancer Res. 1995 Sep 15;55(18):3973-5. Cancer Res. 1995. PMID: 7664265

7

A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase.

Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi CY, Yu MC, Henderson BE, Reichardt JK. Makridakis N, et al. Among authors: reichardt jk. Cancer Res. 1997 Mar 15;57(6):1020-2. Cancer Res. 1997. PMID: 9067262

8

Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility.

Ross RK, Pike MC, Coetzee GA, Reichardt JK, Yu MC, Feigelson H, Stanczyk FZ, Kolonel LN, Henderson BE. Ross RK, et al. Among authors: reichardt jk. Cancer Res. 1998 Oct 15;58(20):4497-504. Cancer Res. 1998. PMID: 9788589 Review.

9

Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA.

Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE, Reichardt JK. Makridakis NM, et al. Among authors: reichardt jk. Lancet. 1999 Sep 18;354(9183):975-8. doi: 10.1016/S0140-6736(98)11282-5. Lancet. 1999. PMID: 10501358

10

Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II.

Makridakis NM, di Salle E, Reichardt JK. Makridakis NM, et al. Among authors: reichardt jk. Pharmacogenetics. 2000 Jul;10(5):407-13. doi: 10.1097/00008571-200007000-00004. Pharmacogenetics. 2000. PMID: 10898110

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

136 results

Search Page

Filters